The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure

Cell Metabolism

Volumn 30, Issue 5, 2019, Pages 847-849

  Bhatt, Deepak L ^a   Verma, Subodh ^b   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; DAPAGLIFLOZIN; GLUCOSE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIURESIS; GLUCOSE BLOOD LEVEL; HEART AFTERLOAD; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; NATRIURESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; COMORBIDITY; CONTROLLED STUDY; HEART STROKE VOLUME; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART FAILURE; HUMANS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85074191209     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2019.10.008     Document Type: Short Survey

References (13)

1. Braunwald, E. (2015). The war against heart failure: the Lancet lecture. Lancet 385, 812-824.
2. Byrne, N.J., Parajuli, N., Levasseur, J.L., Boisvenue, J., Beker, D.L., Masson, G., Fedak, P.W.M., Verma, S., and Dyck, J.R.B. (2017). Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl. Sci. 2, 347-354.
3. Connelly, K.A., Bhatt, D.L., and Verma, S. (2018). Can we DECLARE a victory against cardio-renal disease in diabetes? Cell Metab. 28, 813-815.
4. Connelly, K.A., Zhang, Y., Visram, A., Advani, A., Batchu, S.N., Desjardins, J.F., Thai, K., and Gilbert, R.E. (2019). Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl. Sci. 4, 27-37.
5. Hess, D.A., Terenzi, D.C., Trac, J.Z., Quan, A., Mason, T., Al-Omran, M., Bhatt, D.L., Dhingra, N., Rotstein, O.D., Leiter, L.A., et al. (2019). SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab. 30, 609-613.
6. Lopaschuk, G.D., and Verma, S. (2016). Empagliflozin's fuel hypothesis: not so soon. Cell Metab. 24, 200-202.
7. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Koeber, L., Kosiborod, M.N., Martinez, F.A., Ponikowski, P., Sabatine, M.S., Anand, I.S., Belohlavek, J., et al.; DAPA-HF Trial Committees and Investigators (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. Published online September 19, 2019. 10.1056/NEJMoa1911303.
8. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S.D., Hoffman, E.B., et al., SAVOR-TIMI 53 Steering Committee and Investigators, 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326.
9. Verma, S., Rawat, S., Ho, K.L., Wagg, C.S., Zhang, L., Teoh, H., Dyck, J.E., Uddin, G.M., Oudit, G.Y., Mayoux, E., et al. (2018). Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl. Sci. 3, 575-587.
10. Verma, S., Mazer, C.D., Yan, A.T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M.E., Fitchett, D.H., et al.; EMPA-HEART CardioLink-6 Investigators (2019). Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. Published August 22, 2019. 10.1161/CIRCULATIONAHA.1119.042375.
11. Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., Zelniker, T.A., Kuder, J.F., Murphy, S.A., et al.; DECLARE-TIMI 58 Investigators (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347-357.
12. Zelniker, T.A., and Braunwald, E. (2018). Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J. Am. Coll. Cardiol. 72, 1845-1855.
13. Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Furtado, R.H.M., et al. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31-39.